Enhertu Is First ADC Approved For Tumor-Agnostic Indication

The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.

rainbow — Enhertu is approved for use across a broad spectrum of HER2-positive tumors • Source: Shutterstock

The HER2-directed antibody drug conjugate (ADC) Enhertu (fam-trastuzumab deruxtecan) is the first ADC to be approved for a broad tumor-agnostic indication, setting a path that others could follow.

Partners Daiichi Sankyo Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

08 May 2025

• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).